1Hiorn L R,Swansbury G J,Mehta J,etal.Additional chromosome abnormalities confer worse prognosis in acute promyelocyticleukemia.Br J Hematol,1997,96:314～321
2Chou W C,Tang J L,Yao M,et al.Clinical and biological characteristics of acutepromyelocytic leukemia in taiwan:a high relapse rate in patients with high initial andpeak white blood cell counts during all-trans retinoic acid treatment,Leukemia,1997,11:921～928
3Schoch C,Haase D,Gudat H,et al.Fifty-one patients with acute myeloid leukemia andtranslocation t(8;21)(q22;q22):an additional deletion in 9q is an adverse prognosticfactor.Leukemia,1996,10:1288～1295
4Licht J D,Chomienne C,Goy A,et al.Clinical and molecular characterization of a raresyndrome of acute promyelocytic leukemia associated with translocation(11;17).Blood,1995,85:1083～1094
6Galieni P,Marotta G,Vessichelli F,et al.Variant t(1;15;17)(q23;q22;q23) in a caseof acute promyelocytic leukemia.Leukemia,1996,10:1658～1661
7Saitoh K,Miura I,Kobayashi Y,et al.A new variant transiocation of t(15;17) in apatient with acute promyelocytic leukemia (M3):t(15;19;17)(q22;p13;q12).CancerGenet Cytogenet 1998,102:15～18
8Yamamoto K,Hamaguchi H,Nagata K,et al.A new complex translocation(15;20;17)(q22;p13;q21) in acute promyelocytic leukemia.Cancer Genet Cytogenet 1998,101:89～94
9Chong Y Y,Wong G C,Lau L C,et al.Acute promyelocytic leukemia with a dicentricchromosome involving chromosomes 11,17,and 18.Cancer Genet Cytogenet,1998,105:69～73
10Grimwade D,Howe K,Langabeer S,et al.Establishing the presence of the t(15;17) insuspected acute promyelocytic leukemia:cytogenetic,molecular and PML immunofluorescenceassessment of patients entered into the M.R.C. ATRA trial.Br J Hematol,1996,94:557～573
收稿 1999-01-04
1MIRI-MOGHADDAM E, DEEZAGI A, SOHEILI ZS, et al. Apoptosis and reduced cell proliferation of HL-60 cell line caused by human te- lomerase reverse transcriptase inhibition by siRNA [ J]. Acta Haema- tol,2010,124(2) :72-78.
3FAN Y, LIU Z, FANG X, et al. Differential expression of full-length telomerase reverse transcriptase mRNA and telomerase activity be- tween normal and malignant renal tissues [ J 1. Clinical Cancer Re- sarch ,2005,11 ( 12 ) :4 331-4 337.
4FUJIMOTO K, TAKAHASHI M. Telomerase activity in human leuke- mic cell lines is inhibited by antisense pentadecadeoxynucleotides targeted against c-myc mRNA[ J]. Biochemical and Biophysical Re- sarch Communications, 1997,241 ( 3 ) :775-781.
5MEYERSON M, COUNTER CM, EATON EN, et al. hEST2, the pu- tative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization[ J ]. Cell, 1997,90 (4) :785- 795.
6TAKAKURA M, KYO S, KANAYA T, et al. Cloning of human telom- erase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activa- tion in immortalized and cancer cells [ J ]. Cancer Research, 1999,59 (3) :551-557.
7PAPANIKOLAOU V, ATHANASSIOU E, DUBOS S, et al. hTERT regulation by NF-kappaB and c-mye in irradiated HER2-positive breast cancer ceils [ J ]. International journal of Radiation Biology, 2011,87(6) :609-621.
8SAGAWA Y, NISHI H, ISAKA K, et al. The correlation of TERT ex- pression with e-mye expression in cervical cancer [ J ]. Cancer Let- ters,2001,168( 1 ) :45-50.
